Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials. (18th May 2015)

• Record Type: Journal Article
• Authors: Bhargava, Pavan; Lang, Andrew; Al-Louzi, Omar; Carass, Aaron; Prince, Jerry; Calabresi, Peter A.; Saidha, Shiv
• Other Names: Bruck Wolfgang Academic Editor.
• Is Part Of: Multiple sclerosis international. Volume 2015(2015)
• Publication Date: 2015-05-18
• Subjects: Multiple sclerosis -- Periodicals; 616.834005
• DOI: 10.1155/2015/136295
• Languages: English
• ISSNs: 2090-2654

Abstract

Abstract : Background . The lack of segmentation algorithms operative across optical coherence tomography (OCT) platforms hinders utility of retinal layer measures in MS trials. Objective . To determine cross-sectional and longitudinal agreement of retinal layer thicknesses derived from an open-source, fully-automated, segmentation algorithm, applied to two spectral-domain OCT devices. Methods . Cirrus HD-OCT and Spectralis OCT macular scans from 68 MS patients and 22 healthy controls were segmented. A longitudinal cohort comprising 51 subjects (mean follow-up: 1.4 ± 0.9 years) was also examined. Bland-Altman analyses and interscanner agreement indices were utilized to assess agreement between scanners. Results . Low mean differences (−2.16 to 0.26 μ m) and narrow limits of agreement (LOA) were noted for ganglion cell and inner and outer nuclear layer thicknesses cross-sectionally. Longitudinally we found low mean differences (−0.195 to 0.21 μ m) for changes in all layers, with wider LOA. Comparisons of rate of change in layer thicknesses over time revealed consistent results between the platforms. Conclusions . Retinal thickness measures for the majority of the retinal layers agree well cross-sectionally and longitudinally between the two scanners at the cohort level, with greater variability at the individual level. This open-source segmentation algorithm enables combining data from different OCT platforms, broadening utilization of OCT as an outcome measure in MS trials.